S100A8/A9 in Kidney Diseases: Mechanisms, Spatiotemporal Regulation, Biomarker Potential, and Therapeutic Implications Authors: Meng-ge Zhu, Meng-dan Lu, Jia-wei Cao, Yue-wen Tang, Feng Wan Published: 2026 ABSTRACT AbstractS100A8/A9 (calprotectin) is increasingly recognized as an inflammatory mediator and a potential biomarker and therapeutic target in kidney diseases. However, its roles appear to vary across different stages and contexts of renal injury and repair, yet these changes remain incompletely understood. This narrative review synthesizes evidence from PubMed, Web of Science, and Scopus, supplemented by manual reference screening. Current evidence indicates that S100A8/A9 promotes immune activation, tubular injury, and fibrotic remodeling in diverse renal disorders. Emerging findings further suggest that its effects vary according to disease stage, cellular source, receptor usage, and the local microenvironment, with S100A8/A9 predominantly amplifying early inflammatory injury while potentially contributing to inflammation resolution and tissue repair at later stages. We therefore propose a spatiotemporal framework that extends beyond previous disease- or pathway-centered perspectives by integrating the timing and cellular context of S100A8/A9 signaling. Altered S100A8/A9 levels in blood, urine, feces, and extracellular vesicles also show potential for disease detection, differential diagnosis, monitoring, and prognostic assessment, while pharmacological inhibition of this axis has produced renoprotective effects in preclinical models. Nevertheless, heterogeneous models, limited cell- and receptor-specific evidence, uncertain therapeutic windows, and insufficient prospective clinical validation hinder translation. Longitudinal clinical studies and spatial and single-cell analyses are needed to establish stage-specific biomarker and therapeutic strategies targeting S100A8/A9 in precision nephrology. Introduction Inflammation is a fundamental hallmark of kidney diseases, yet the endogenous signals that dynamically orchestrate the transition from tissue injury to repair remain incompletely understood.1 Among these, S100A8/A9 (calprotectin), a myeloid-derived damage-associated molecular pattern (DAMP), has emerged as a critical mediator at the interface of innate immunity and renal pathology.2,3 Upon release from activated or injured cells, S100A8/A9 binds to pattern recognition receptors such as Toll-like receptor 4 (TLR4) and the receptor for advanced glycation end products (RAGE), thereby amplifying inflammatory signaling, promoting immune cell recruitment, and modulating epithelial and stromal cell responses.4–9 Accumulating evidence indicates that S100A8/A9 exerts paradoxical and context-dependent functions across kidney diseases. On the one hand, it acts as a potent amplifier of early inflammatory injury, driving tubular damage, immune activation, and fibrotic remodeling.10,11 On the other hand, some studies suggest that S100A8/A9 also contributes to tissue repair and resolution of inflammation during later stages, particularly through modulation of macrophage polarization and epithelial regeneration.12 These findings challenge the view of S100A8/A9 as a solely harmful mediator and suggest that its effects depend on disease stage, cellular source, receptor usage, and the local microenvironment. Beyond its mechanistic roles, S100A8/A9 has gained increasing attention as a potential clinical biomarker. Its elevated levels in blood, urine, feces, and extracellular vesicles have demonstrated potential for early detection, differential diagnosis, and prognostic stratification across a wide spectrum of kidney diseases.13–16 Moreover, pharmacological targeting of the S100A8/A9 signaling axis has shown renoprotective effects in multiple preclinical models.10,17–19 However, the translational application of these findings remains limited by an incomplete understanding of its temporal dynamics, cell-specific sources, and receptor-specific signaling mechanisms. Here, we propose a spatiotemporal framework in which S100A8/A9 functions as a dynamic, context-dependent regulator of the transition from inflammatory injury to tissue repair within the renal microenvironment. By integrating mechanistic insights with emerging clinical evidence, we aim to clarify S100A8/A9 not only as a potential biomarker or inflammatory mediator but as a context-dependent regulator with significant implications for precision nephrology (Figure 1). Figure 1Overview of the biological roles and clinical applications of S100A8/A9 in kidney diseases. S100A8/A9 is released mainly from myeloid cells and stressed renal tubular epithelial cells and activates TLR4- and RAGE-related signaling, promoting inflammation, tubular injury, fibrosis, and tumor progression. S100A8/A9 also has potential clinical applications as a biomarker in blood, urine, feces, and extracellular vesicles for early detection, etiological differentiation, disease monitoring, and prognostic assessment, and as a potential therapeutic target through small-molecule inhibitors, natural compounds, and upstream modulation.The diagram illustrates the roles of S100A8/A9 (Calprotectin) in kidney diseases. Myeloid cells or TECs release S100A8/A9 through passive release (Necrosis, NETs) or active secretion. S100A8/A9 activates TLR4 and RAGE pathways. TLR4 leads to MyD88 and NF-kB/NLRP3 inflammasome, causing inflammation, tubular injury, fibrosis and tumor progression. RAGE leads to NF-kB/ERK and Cytokines/ROS. Clinical applications include biomarkers in blood, urine, feces and extracellular vesicles for early detection, etiological differentiation, disease monitoring and prognostic assessment. Therapeutic strategies involve small-molecule inhibitors, natural compounds and upstream modulation.S100A8/A9 in kidney disease: release, signaling, effects, clinical uses. Overview of the biological roles and clinical applications of S100A8/A9 in kidney diseases. S100A8/A9 is released mainly from myeloid cells and stressed renal tubular epithelial cells and activates TLR4- and RAGE-related signaling, promoting inflammation, tubular injury, fibrosis, and tumor progression. S100A8/A9 also has potential clinical applications as a biomarker in blood, urine, feces, and extracellular vesicles for early detection, etiological differentiation, disease monitoring, and prognostic assessment, and as a potential therapeutic target through small-molecule inhibitors, natural compounds, and upstream modulation. To improve transparency, relevant literature was identified through searches of PubMed, Web of Science, and Scopus using combinations of (“S100A8/A9” OR “S100A8/S100A9” OR “S100A8 and S100A9” OR “calprotectin” OR “MRP8/MRP14”) AND (“kidney disease” OR “renal disease”). Additional studies were identified by screening the reference lists of key articles and were selected based on their relevance and the quality of the available evidence. Biological Characteristics of S100A8/A9 Molecular Architecture of S100A8/A9 S100A8 and S100A9 belong to calcium-binding members of the S100 protein family, encoded within the gene cluster on chromosome 1q21, a region notable for its high genetic variability.20,21 The two proteins differ in size and composition, with S100A8 comprising 93 amino acids (10.8 kDa) and S100A9 consisting of 113 amino acids (13.2 kDa).22 Structurally, each protein contains two EF-hand helix-loop-helix motifs connected by a flexible linker, a feature that underlies their capacity for dimerization.23 S100A8 and S100A9 can function individually and can form homodimers, heterodimers, and higher-order oligomers.24,25 However, because the corresponding homodimers are relatively less stable, S100A8 and S100A9 preferentially assemble into the S100A8/A9 heterodimer, known as calprotectin, which represents the predominant form under physiological conditions and is widely implicated in inflammatory responses.26–28 In the presence of elevated Ca2+ concentrations, S100A8/A9 heterodimers can further assemble into tetrameric structures, which are also closely associated with their biological functions.26 Unless otherwise specified, the term “S100A8/A9” in this review refers to the heterodimer, whereas S100A8 or S100A9 is used when the cited study specifically investigated the individual protein. Cellular Origin, Release, and Functional Identity of S100A8/A9 S100A8/A9 is predominantly expressed in myeloid cells such as neutrophils, monocytes, dendritic cells, and activated macrophages, and can also be induced in keratinocytes and epithelial cells under inflammatory conditions, making it a major source in both physiological and inflammatory states.29–36 In neutrophils, it accounts for a large fraction of cytosolic proteins, underscoring its role as a readily available inflammatory mediator.37 Upon stimulation or cellular stress, S100A8/A9 can be released into the extracellular space through either passive mechanisms, such as cell damage, necrosis, or neutrophil extracellular trap (NET) formation, or active Ca2+-dependent pathways involving its translocation to the plasma membrane.38–41 Notably, this active secretion bypasses the classical Golgi pathway42–44 and instead relies on alternative mechanisms that can be enhanced by inflammatory signals and intracellular pathways such as protein kinase C activation.42,45,46 Once released, S100A8/A9 acts as a key mediator of innate immunity by promoting leukocyte recruitment and amplifying inflammatory signaling in response to tissue injury.47 It is also known by several alternative names, including MRP8/MRP14, calgranulin A/B, and calprotectin, the latter being most commonly used and reflecting its antimicrobial and immunoregulatory functions.42,48 Collectively, these features highlight its central role in coordinating inflammatory and immune responses. Main Receptors and Downstream Signaling Pathways in Kidney Disease TLR4 and RAGE are the two common receptors mediating S100A8/A9 signaling in kidney diseases. Both function as pattern recognition receptors and initiate overlapping yet context-dependent inflammatory and stress-response pathways that contribute to renal injury and disease progression. TLR4 TLR4 is a member of the Toll-like receptor family that functions as a transmembrane pattern recognition receptor in innate immunity. It is composed of an extracellular leucine-rich repeat domain for ligand recognition, a transmembrane region, and a cytoplasmic Toll/interleukin-1 receptor (TIR) domain.49 Upon activation, TLR4 recruits adaptor proteins such as myeloid differentiation primary response 88 (MyD88) and TIR-domain-containing adaptor inducing interferon-β (TRIF), leading to the activation of downstream signaling pathways including NF-κB and MAPKs, thereby driving inflammatory responses.50,51 The S100A8/A9–TLR4 axis represents a central pro-inflammatory pathway, particularly in acute kidney injury (AKI). In ischemia–reperfusion injury (IRI), S100A9 initiates robust inflammatory cascades through TLR4 activation, leading to amplified cytokine production and tubular damage.10 Consistently, integrated proteomic and transcriptomic analyses identified S100A8/A9 as one of the most prominently upregulated inflammatory mediators during the early reperfusion phase.11 In addition, S100A8/A9 directly acts on tubular epithelial cells (TECs), activating TNF signaling and promoting inflammatory injury, with IL-17 signaling additionally implicated by transcriptomic analyses.52 In contrast-associated AKI induced by iopromide, both in rat models and NRK-52E cells, the entire S100A8/A9-TLR4-NLRP3 inflammasome axis is markedly upregulated.53 Beyond acute injury, TLR4-dependent signaling also contributes to chronic renal remodeling. In diabetic nephropathy (DN), S100A8/A9 promotes epithelial-mesenchymal transition (EMT) of tubular cells through activation of the TLR4/NF-κB pathway, thereby facilitating fibrosis and disease progression.18 Additionally, S100A9 promotes renal inflammatory injury by activating the TLR4-p38/MAPK-LCN2 signaling pathway, thereby contributing to the formation of calcium oxalate stones.54 RAGE RAGE is a pattern recognition receptor of the immunoglobulin superfamily expressed on macrophages, endothelial cells, dendritic cells, and tumor cells.55 It binds diverse ligands, including HMGB1, S100 proteins, and advanced glycation end products, thereby activating multiple intracellular signaling pathways.56,57 Structurally, RAGE consists of an extracellular ligand-binding region with one V-type and two C-type domains, a transmembrane segment, and a short cytoplasmic tail required for signal transduction.58 Through these features, RAGE serves as a key mediator of inflammatory and stress-related responses. RAGE-mediated signaling represents another critical axis, particularly in chronic and proliferative kidney diseases. In autosomal dominant polycystic kidney disease (ADPKD), the S100A8/A9–RAGE–NF-κB/ERK signaling pathway acts as a key driver of cyst growth and disease progression.59 Collectively, these findings indicate that S100A8/A9 signals through TLR4- and RAGE-dependent pathways to orchestrate a spectrum of downstream responses, including inflammation, inflammasome activation, epithelial plasticity, and tumor progression. The relative contribution of each pathway appears to be highly context-dependent, varying across acute versus chronic injury and inflammatory versus neoplastic settings, which has important implications for the development of targeted therapeutic strategies. Mechanistic Programs of S100A8/A9 in Kidney Disease Emerging evidence demonstrates that S100A8/A9 is consistently upregulated across a broad spectrum of kidney diseases, including AKI,10 chronic kidney disease (CKD),13 lupus nephritis (LN),60 nephrotoxic serum nephritis (NTSN),61 and ANCA-associated vasculitis (AAV),62 ADPKD,59 renal cell carcinoma (RCC),63 and kidney stone disease64 (Figure 2). Beyond serving as a marker of tissue injury, S100A8/A9 acts as a key pathogenic mediator by orchestrating inflammatory signaling, immune cell interactions, parenchymal injury, and fibrotic remodeling. The interconnected mechanisms are summarized below. Figure 2Pathological roles of S100A8/A9 in kidney disease. S100A8/A9 (calprotectin) participates in distinct pathological processes across multiple kidney diseases. In AKI, it promotes inflammation, tubular injury and apoptosis, pyroptosis, and subsequent fibrotic remodeling. In immune-mediated kidney diseases, including lupus nephritis (LN), ANCA-associated vasculitis (AAV), and nephrotoxic serum nephritis (NTSN), S100A8/A9 is associated with immune activation, inflammatory amplification, and disease activity. In CKD, it drives macrophage-to-myofibroblast transition (MMT), renal fibrosis, and vascular calcification, and also shows prognostic value. In ADPKD, S100A8/A9 contributes to inflammation and tubular epithelial cell (TEC) proliferation. In renal cell carcinoma (RCC), it is involved in tumor-associated inflammation, an immunosuppressive microenvironment, and tumor progression. In kidney stone disease, S100A8/A9 contributes to renal inflammation, M1 macrophage polarization, and calcium oxalate stone formation.A schematic infographic centers on an oval labeled S100A8/A9 (Calprotectin) with small A8 and A9 circles above it. Colored arrows radiate outward to six surrounding panels, each with a kidney-themed icon and bullet points. The panels are titled AKI, ADPKD, RCC, Kidney stones, CKD and LN/AAV/NTSN. Each box lists key downstream effects (eg, iniflammatory responses, cell injury or death pathways, tissue scarring, immune signaling, tumor-related changes, vascular mineral buildup, epithelial proliferation and stone development), visually summarizing how the central molecule is connected to multiple renal conditions.Infographic linking calprotectin to AKI, CKD, ADPKD, immune nephritis, RCC and stones. Pathological roles of S100A8/A9 in kidney disease. S100A8/A9 (calprotectin) participates in distinct pathological processes across multiple kidney diseases. In AKI, it promotes inflammation, tubular injury and apoptosis, pyroptosis, and subsequent fibrotic remodeling. In immune-mediated kidney diseases, including lupus nephritis (LN), ANCA-associated vasculitis (AAV), and nephrotoxic serum nephritis (NTSN), S100A8/A9 is associated with immune activation, inflammatory amplification, and disease activity. In CKD, it drives macrophage-to-myofibroblast transition (MMT), renal fibrosis, and vascular calcification, and also shows prognostic value. In ADPKD, S100A8/A9 contributes to inflammation and tubular epithelial cell (TEC) proliferation. In renal cell carcinoma (RCC), it is involved in tumor-associated inflammation, an immunosuppressive microenvironment, and tumor progression. In kidney stone disease, S100A8/A9 contributes to renal inflammation, M1 macrophage polarization, and calcium oxalate stone formation. Inflammatory Amplification Axis As a DAMP, S100A8/A9 amplifies renal inflammation primarily through engagement of pattern recognition receptors, including TLR4 and RAGE, thereby activating downstream NF-κB signaling pathways. In AKI, this pro-inflammatory role is evident across multiple models.10,11 In IRI, early infiltration of S100A9+Ly6C+ macrophages initiate inflammatory cascades via the S100A8/A9–TLR4 axis.10 In sepsis-associated AKI, pharmacological blockade of S100A9 attenuates the systemic inflammatory response and mitigates renal injury.17 Similarly, in contrast-induced AKI, components of the S100A8/A9–TLR4–NLRP3 inflammasome axis are markedly upregulated. Inhibition of TLR4 or NLRP3 reduces reactive oxygen species production and cellular injury, suggesting that this pathway contributes to contrast-induced renal damage.53 Beyond AKI, S100A8/A9 also drives inflammation in immune-mediated kidney diseases. In NTSN, elevated S100A8/A9 promotes a robust inflammatory amplification loop through autocrine and paracrine signaling, inducing cytokine production in macrophages, mesangial cells, and endothelial cells, thereby enhancing intercellular crosstalk within the glomerulus.61 In LN and AAV, elevated serum and urinary S100A8/A9 levels are associated with disease activity and renal inflammation,60,65 while mechanistic studies in MPO-AAV further implicate TLR4- and RAGE-dependent signaling in S100A8/A9-mediated inflammatory responses.66 In kidney stone disease, S100A8 and S100A9 are enriched in stone matrices and are associated with inflammatory pathways and stone formation.16,54,64,67,68 Mechanistically, calcium oxalate crystals promote IL-6 release from TECs, which increases S100A8 and S100A9 expression in M1 macrophages and amplifies crystal formation, while S100A9 further activates TLR4-p38/MAPK signaling in TECs to induce LCN2 expression and enhance macrophage recruitment and M1 polarization.54,69 In ADPKD, the S100A8/A9–RAGE–NF-κB/ERK signaling axis further drives disease progression by enhancing inflammatory responses and promoting TECs proliferation.59 In RCC, the expression of S100A8 and S100A9 is associated with tumor progression and prognosis,70–72 while S100A9 is also linked to an immunosuppressive tumor microenvironment.73 Furthermore, S100A8/A9 reflects systemic inflammation in type 2 diabetes (T2D). In the general population, elevated plasma S100A8/A9 levels are associated with an increased risk of developing T2D, potentially serving as a modifiable inflammatory biomarker.13 Collectively, these findings establish S100A8/A9 as a central amplifier of renal inflammation across diverse pathological contexts. Tubular Epithelial Injury and Death Axis In addition to its pro-inflammatory effects, S100A8/A9 directly contributes to renal parenchymal injury by inducing TECs damage and apoptosis. In sepsis-associated AKI, renal S100A9 expression increases in a time-dependent manner at both mRNA and protein levels. Mechanistically, inhibition of S100A9 attenuates TECs apoptosis and improves mitochondrial function, underscoring its role in mediating epithelial cell injury.17 In IRI, S100A8/A9 can directly act on TECs, through activating TNF signaling to exacerbate tissue damage.52 Similarly, in iopromide-induced contrast-associated AKI (in both rat models and NRK-52E cells), the S100A8/A9-TLR4-NLRP3 inflammasome axis is markedly upregulated. Inhibition of TLR4 or knockdown of NLRP3 significantly reduces TECs apoptosis, supporting a critical role for S100A8/A9 in inflammasome-mediated tubular injury.53 In sepsis-associated AKI, knockdown of S100A9 significantly reduces the expression of pyroptosis-related markers, including cleaved NLRP3, CASP1, GSDMD-N, and cleaved IL-1β, suggesting that S100A9 contributes to pyroptosis by promoting NLRP3 inflammasome activation.74 Fibrotic Remodeling Axis S100A8/A9 further contributes to kidney disease progression by promoting EMT and renal fibrosis. In UUO models, renal S100A8/A9 expression rises time-dependently, predominantly in infiltrating granulocytes, paralleling findings in human obstructive nephropathy.75 Importantly, S100A9 deficiency attenuates fibrosis without altering inflammatory cytokine levels, indicating direct profibrotic actions on TECs. Mechanistically, S100A8/A9 ablation prevents TECs apoptosis and EMT-like phenotypic shifts; conversely, recombinant S100A8/A9 disrupts epithelial polarity, arrests cell cycle progression, and induces apoptosis in vitro. This profibrotic role extends to DN, where S100A8/A9 is markedly upregulated in renal epithelial cells (RECs).18 Silencing S100A8/A9 inhibits EMT and mitigates tubulointerstitial fibrosis, while forced expression aggravates these pathological changes. Recent study found S100A8/A9 is significantly upregulated in fibrotic kidneys of CKD and is predominantly expressed in macrophages exhibiting a macrophage-to-myofibroblast transition (MMT) phenotype, thereby promoting renal interstitial fibrosis by facilitating the transition of M2 macrophages into myofibroblasts.3 Mechanistically, S100A8/A9 drives the MMT process via activation of the TLR4/MyD88/NF-κB signaling pathway, while its knockdown or pharmacological inhibition markedly attenuates fibrosis.3 In addition, S100A8/A9 contributes to CKD-associated vascular calcification, which can be attenuated by S100A9 inhibition or blockade of its downstream signaling pathways.19 Taken together, these data identify S100A8/A9 as a critical mediator of fibrotic remodeling through direct regulation of EMT and epithelial integrity, operating independently of its canonical pro-inflammatory functions. Spatiotemporal Regulation of S100A8/A9 in IRI S100A8/A9 exhibits a distinct spatiotemporal regulatory pattern in IRI, characterized by a functional shift from early pro-inflammatory injury to later tissue repair (Figure 3). In the early phase (within 2 hours after injury), S100A9+Ly6C+ macrophages rapidly infiltrate the kidney and initiate pro-inflammatory cascades via the S100A8/A9-TLR4 axis.10 Consistently, in human AKI biopsies and transplanted kidneys, infiltration of S100A8/A9+ cells correlate with tissue damage and specific immune cell subsets, supporting the clinical relevance of this mechanism.10,11 At the mechanistic level, S100A8/A9 amplifies injury through innate immune activation and direct effects on TECs, with TNF signaling identified as a major downstream pathway and IL-17 signaling additionally implicated by transcriptomic analyses.52 However, this detrimental role is temporally restricted. During the later repair phase (days 5–10), S100A9 deficiency disrupts macrophage-mediated renal repair.12 Although M1-associated markers remain largely unchanged, S100A9-deficient kidneys show sustained macrophage accumulation and increased expression of M2-associated markers, including Arg1, IRF4, and MGL1. This dysregulated M2 macrophage response is accompanied by persistent inflammation, delayed renal recovery, and aggravated fibrosis, suggesting that S100A8/A9 is required for the appropriate regulation of macrophage-mediated tissue repair after IRI. Emerging evidence further indicates that activated SOX9+ RECs contribute to post-injury kidney repair through their secretory activity.76 S100A9 has been identified as a key bioactive component of the SOX9+ RECs secretome, and exogenous S100A9 promotes resident SOX9+ RECs proliferation and attenuates tubular injury.76 In addition, the SOX9+ RECs secretome may facilitate renal regeneration by mediating intercellular communication among TECs, immune cells, and vascular endothelial cells. The mechanisms underlying this stage-dependent functional shift remain incompletely defined and are unlikely to involve a single molecular switch. Instead, the biological effects of S100A8/A9 may be shaped by dynamic changes in the renal microenvironment, including cellular sources, responding cell populations, receptor engagement, and the local cytokine milieu. During early injury, myeloid cell-derived S100A8/A9 predominantly activates TLR4-dependent inflammatory signaling, whereas during repair, S100A9 may support pro-reparative macrophage polarization and epithelial–immune crosstalk. However, the receptor-specific pathways responsible for these later reparative effects remain to be established. Importantly, direct evidence for this spatiotemporal functional shift is currently limited to IRI models. Whether a similar transition occurs in chronic kidney diseases remains unknown, as current studies in chronic settings primarily link sustained S100A8/A9 expression to inflammation and fibrotic remodeling rather than stage-specific reparative functions. Together, these findings support a dual and time-dependent role for S100A8/A9 in IRI. Early inhibition may reduce acute inflammation and tubular injury, whereas prolonged or non-selective blockade could interfere with subsequent repair, highlighting the potential value of time-restricted and cell-specific therapeutic strategies. Figure 3Spatiotemporal roles of the S100A8/A9 axis in IRI. In the early injury phase, S100A8/A9 derived from infiltrating inflammatory macrophages activates TLR4–MyD88–NF-κB signaling and directly acts on tubular epithelial cells, promoting inflammation, tubular injury, apoptosis, and fibrotic progression. In the late repair phase, S100A9 deficiency leads to sustained macrophage accumulation, increased M2-associated markers, delayed recovery, and aggravated fibrosis, suggesting a role for S100A8/A9 in macrophage-mediated repair. Activated SOX9+ renal epithelial cells may further support recovery through S100A9-containing secretomes that promote epithelial proliferation and intercellular crosstalk.The diagram outlines the roles of the S100A8/A9 axis in renal ischemia-reperfusion injury (IRI), split into early injury (within 2 hours) and late repair phases (days 5-10). Early injury involves S100A9 high Ly6C high macrophages and S100A8/A9 high macrophages infiltrating the kidney, activating TLR4 and MyD88, leading to NF-kB-mediated inflammation. This affects tubular epithelial cells (TECs), triggering TNF signaling, injury, apoptosis and fibrosis. In the late repair phase, wild-type macrophages support renal repair. In S100A9 knockout conditions, macrophage accumulation persists, with increased M2 markers (Arg1, IRF4, MGL1), ongoing inflammation, delayed recovery and worsened fibrosis. SOX9 positive renal epithelial cells (RECs) secrete S100A9, enhancing REC proliferation and interaction with immune and vascular endothelial cells, aiding repair. Symbols represent macrophages, TECs, RECs, immune cells and vascular endothelial cells.S100A8/A9 in renal IRI: early injury, late repair, macrophage roles, signaling pathways. Spatiotemporal roles of the S100A8/A9 axis in IRI. In the early injury phase, S100A8/A9 derived from infiltrating inflammatory macrophages activates TLR4–MyD88–NF-κB signaling and directly acts on tubular epithelial cells, promoting inflammation, tubular injury, apoptosis, and fibrotic progression. In the late repair phase, S100A9 deficiency leads to sustained macrophage accumulation, increased M2-associated markers, delayed recovery, and aggravated fibrosis, suggesting a role for S100A8/A9 in macrophage-mediated repair. Activated SOX9+ renal epithelial cells may further support recovery through S100A9-containing secretomes that promote epithelial proliferation and intercellular crosstalk. Clinical Applications of S100A8/A9 in Kidney Diseases S100A8/A9 has emerged as a versatile biomarker across the spectrum of kidney diseases, with clinical applications spanning early detection, etiological differentiation, disease monitoring, and prognostic evaluation (Table 1). Beyond its diagnostic value, accumulating evidence also highlights its role as a mediator of inflammation and a potential therapeutic target. The following sections summarize its clinical utility from a function-oriented perspective. Table 1Clinical Applications of S100A8/A9 in Kidney DiseasesApplicationSamplePopulationKey FindingsAUCSensitivitySpecificityRefEarly detection and risk stratificationPlasma4815 initially nondiabetic participants of the Prevention of Renal and Vascular End-stage DiseaseElevated plasma S100A8/A9 is associated with increased risk of T2D///[13]PlasmaCardiac surgery patients with cardiopulmonary bypass (n=39)Early elevation predicts postoperative AKI development0.8185.7%75%[77]PlasmaAcute coronary syndrome patients (n=172)Enables early detection of AKI in high-risk cardiovascular settings0.864//[78]UrineCoronary care unit patients (n=147)Accurately predicts intrinsic AKI in critically ill patients0.946//[79]Urinary extracellular vesiclesDiabetes spectrum (healthy control, diabetes with normal, microalbuminuria, and macroalbuminuria, n=75)Potential non-invasive biomarker for early DN detection and progression///[80]Etiological differentiationUrineAdult cohorts: intrinsic AKI vs prerenal AKI (multiple studies)Reliably distinguishes intrinsic from prerenal AKI; often outperforms NGAL~0.97~90%-93.3%~93%-97.1%[14, 81–83]UrinePediatric cohorts with AKI (multiple studies)High diagnostic accuracy in differentiating structural vs functional AKIUp to 0.99Up to 95.6%Up to 100%[84–86]UrineKidney transplant recipients with graft dysfunction (n=328)Differentiates intrinsic graft injury from prerenal causes0.9490.4%74.1%[87]Urine30 patients with pyelonephritis, 30 patients with cystitis, and 28 healthy controlsCalprotectin aids UTI diagnosis and site differentiation///[88]Disease activity monitoring and relapse predictionSerum/UrineMPO-AAV patients (n=42) and healthy controls (n=10)Serum and urinary s100a8/a9 levels were elevated in active mpo-AAV, with urinary s100a8/a9 also higher than in patients in remission, and were associated with disease severity///[66]SerumAAV patients with acute disease (n=57), disease remission (n=57), and healthy controlsCalprotectin reflects AAV activity and predicts relapse///[62]SerumSeventy-six AAVRising calprotectin predicts renal decline in AAV///[89]Urine/serumBritish Isles Lupus Assessment Group Biologics Register SLE patients (n=243) and matched controls (n=48)Urinary s100a8/a9 was associated with active LN; combined serum s100a8/a9 and s100a12 showed potential for predicting rituximab response///[60]SerumjSLE patients (n=64), matched healthy controls (n=53), and IgA vasculitis controls (n=9)Serum s100a8/a9 was elevated in jsle and associated with active LN///[65]FFPE samplesLupus nephritis patients (n=14) and normal controls (n=10)S100a8 is association with disease severity and activity in LN[90]Prognostic prediction and outcome associationSerumPatients with CKD (n=112) and patients on dialysis (n=171); patients with CKD for confirm (n=170)Elevated calprotectin independently predicts vascular calcification, cardiovascular events, and mortality in CKD///[19]Fecal260 patients low-fecal calprotectin (<102 μg/g, n = 130) and high-fecal calprotectin (≥102 μg/g, n = 130)Fecal calprotectin may be a potential prognostic biomarker for mortality risk in CKD patients///[15]Serum/Biopsy29 RCC patients152 patients with ccRCCPotential non-invasive biomarker for early RCC detection and a prognostic indicator in ccRCC///[63, 70–73, 91, 92]Serum98 kidney transplant recipients who had recovered from COVID-19Serum calprotectin links long Covid, inflammation, and graft injury///[93]Special clinical contexts: transplantation and drug-induced injuryViral allograft injury monitoringBiopsyKidney transplant recipients (n=190; 303 biopsies)Intragraft expression associated with graft outcome and progression///[94, 95]PlasmaKidney transplant recipients with/without BK virus (n=132)Elevated levels reflect viral-associated graft injury and early dysfunction///[96]Urine41 patients who received cisplatin-based treatments for non-small cell lung cancerElevated urinary calprotectin reflects cisplatin renal stress but poorly predicts nephrotoxicity///[97] Table 1Clinical Applications of S100A8/A9 in Kidney DiseasesApplicationSamplePopulationKey FindingsAUCSensitivitySpecificityRefEarly detection and risk stratificationPlasma4815 initially nondiabetic participants of the Prevention of Renal and Vascular End-stage DiseaseElevated plasma S100A8/A9 is associated with increased risk of T2D///[13]PlasmaCardiac surgery patients with cardiopulmonary bypass (n=39)Early elevation predicts postoperative AKI development0.8185.7%75%[77]PlasmaAcute coronary syndrome patients (n=172)Enables early detection of AKI in high-risk cardiovascular settings0.864//[78]UrineCoronary care unit patients (n=147)Accurately predicts intrinsic AKI in critically ill patients0.946//[79]Urinary extracellular vesiclesDiabetes spectrum (healthy control, diabetes with normal, microalbuminuria, and macroalbuminuria, n=75)Potential non-invasive biomarker for early DN detection and progression///[80]Etiological differentiationUrineAdult cohorts: intrinsic AKI vs prerenal AKI (multiple studies)Reliably distinguishes intrinsic from prerenal AKI; often outperforms NGAL~0.97~90%-93.3%~93%-97.1%[14, 81–83]UrinePediatric cohorts with AKI (multiple studies)High diagnostic accuracy in differentiating structural vs functional AKIUp to 0.99Up to 95.6%Up to 100%[84–86]UrineKidney transplant recipients with graft dysfunction (n=328)Differentiates intrinsic graft injury from prerenal causes0.9490.4%74.1%[87]Urine30 patients with pyelonephritis, 30 patients with cystitis, and 28 healthy controlsCalprotectin aids UTI diagnosis and site differentiation///[88]Disease activity monitoring and relapse predictionSerum/UrineMPO-AAV patients (n=42) and healthy controls (n=10)Serum and urinary s100a8/a9 levels were elevated in active mpo-AAV, with urinary s100a8/a9 also higher than in patients in remission, and were associated with disease severity///[66]SerumAAV patients with acute disease (n=57), disease remission (n=57), and healthy controlsCalprotectin reflects AAV activity and predicts relapse///[62]SerumSeventy-six AAVRising calprotectin predicts renal decline in AAV///[89]Urine/serumBritish Isles Lupus Assessment Group Biologics Register SLE patients (n=243) and matched controls (n=48)Urinary s100a8/a9 was associated with active LN; combined serum s100a8/a9 and s100a12 showed potential for predicting rituximab response///[60]SerumjSLE patients (n=64), matched healthy controls (n=53), and IgA vasculitis controls (n=9)Serum s100a8/a9 was elevated in jsle and associated with active LN///[65]FFPE samplesLupus nephritis patients (n=14) and normal controls (n=10)S100a8 is association with disease severity and activity in LN[90]Prognostic prediction and outcome associationSerumPatients with CKD (n=112) and patients on dialysis (n=171); patients with CKD for confirm (n=170)Elevated calprotectin independently predicts vascular calcification, cardiovascular events, and mortality in CKD///[19]Fecal260 patients low-fecal calprotectin (<102 μg/g, n = 130) and high-fecal calprotectin (≥102 μg/g, n = 130)Fecal calprotectin may be a potential prognostic biomarker for mortality risk in CKD patients///[15]Serum/Biopsy29 RCC patients152 patients with ccRCCPotential non-invasive biomarker for early RCC detection and a prognostic indicator in ccRCC///[63, 70–73, 91, 92]Serum98 kidney transplant recipients who had recovered from COVID-19Serum calprotectin links long Covid, inflammation, and graft injury///[93]Special clinical contexts: transplantation and drug-induced injuryViral allograft injury monitoringBiopsyKidney transplant recipients (n=190; 303 biopsies)Intragraft expression associated with graft outcome and progression///[94, 95]PlasmaKidney transplant recipients with/without BK virus (n=132)Elevated levels reflect viral-associated graft injury and early dysfunction///[96]Urine41 patients who received cisplatin-based treatments for non-small cell lung cancerElevated urinary calprotectin reflects cisplatin renal stress but poorly predicts nephrotoxicity///[97] Clinical Applications of S100A8/A9 in Kidney Diseases Early Detection and Risk Stratification S100A8/A9 serves as a potential early warning and risk-stratification biomarker for kidney injury in high-risk clinical settings. In patients undergoing cardiac surgery with cardiopulmonary bypass, plasma S100A8/A9 levels increase rapidly and predict subsequent AKI development with good discriminative performance.77 The magnitude of elevation independently correlates with 7-day AKI risk and remains robust after adjustment for demographic variables, supporting its utility as an early and broadly applicable biomarker. Similarly, in cardiovascular settings such as acute coronary syndrome, both plasma and urinary S100A8/A9 enable early identification and risk stratification of AKI, with performance comparable to established biomarkers such as neutrophil gelatinase-associated lipocalin (NGAL).78,79 In sepsis, higher serum S100A8/A9 levels at intensive care unit admission are independently associated with subsequent sepsis-associated AKI and may improve early risk stratification when combined with Sequential Organ Failure Assessment scores.98 Consistently, elevated serum and urinary S100A9 levels have been observed in sepsis-associated AKI, with experimental evidence implicating S100A9 in NLRP3 inflammasome-mediated renal inflammation and pyroptosis.74 In addition to early risk assessment, urinary S100A8/A9 may also provide etiological information in AKI, with potential value for distinguishing intrinsic from pre-renal injury.81 Evidence further suggests that S100A8/A9, particularly when detected in urinary extracellular vesicles, may serve as an early biomarker in DN, highlighting its potential in preclinical disease detection.80 In addition, elevated plasma S100A8/A9 is associated with higher T2D risk, but is not causally linked.13 Compared with established biomarkers used in kidney injury assessment, S100A8/A9 appears to provide complementary information rather than replacing existing markers99–101 (Table 2). NGAL and KIM-1 mainly reflect tubular injury,101–105 whereas cystatin C primarily indicates changes in glomerular filtration and IL-18 is associated with inflammatory tubular injury.106–109 In contrast, S100A8/A9 more closely reflects myeloid-cell activation and inflammatory responses. However, its kidney specificity is limited by systemic inflammatory conditions and infection, and standardized assays and disease-specific cutoff values remain lacking. Direct comparisons with established biomarkers are still scarce, making it unclear which approach offers better diagnostic performance. Table 2Comparison of S100A8/A9 with Established Kidney Injury BiomarkersBiomarkerCellular SourceSample TypeClinical ApplicationsMajor LimitationsS100A8/A977–79Predominantly neutrophils and monocytes/macrophages; can also be induced in renal epithelial cells under inflammatory conditionsBlood/UrineEarly AKI detection and risk stratification; differentiation of intrinsic from prerenal AKI; disease activity monitoring and prognostic assessmentLimited kidney specificity; influenced by systemic inflammation and infection; lack of standardized assays and disease-specific cutoff valuesNGAL101–104Renal tubular epithelial cells and neutrophilsBlood/UrineEarly AKI detection and risk prediction; differentiation of intrinsic from prerenal AKI; prediction of non-recovery, RRT, and mortality; early indication of tubular injury before eGFR declineVariable performance across clinical settings; affected by comorbidities, measurement timing, cutoff values, and systemic inflammationKIM-1104,105Proximal tubular epithelial cellsUrineEarly detection of proximal tubular injury; assessment of AKI severity and duration; prediction of dialysis and mortalityVariable performance across clinical settings; limited independent prognostic value; further validation in larger populations is requiredCystatin C106,107Nucleated cellsBloodEarly detection of GFR decline; assessment of renal function; may indicate functional deterioration earlier than serum creatinineAffected by nonrenal factors; does not identify the site or cause of kidney injury; prognostic performance for AKI outcomes is inconsistentIL-18108,109Immune cells and injured tubular cellsBlood/UrineEarly detection and risk prediction of inflammatory or ischemic AKI; assessment of AKI severity and adverse outcomes, including mortalityVariable diagnostic performance across clinical settings; influenced by measurement timing and systemic inflammation; limited kidney specificity Table 2Comparison of S100A8/A9 with Established Kidney Injury BiomarkersBiomarkerCellular SourceSample TypeClinical ApplicationsMajor LimitationsS100A8/A977–79Predominantly neutrophils and monocytes/macrophages; can also be induced in renal epithelial cells under inflammatory conditionsBlood/UrineEarly AKI detection and risk stratification; differentiation of intrinsic from prerenal AKI; disease activity monitoring and prognostic assessmentLimited kidney specificity; influenced by systemic inflammation and infection; lack of standardized assays and disease-specific cutoff valuesNGAL101–104Renal tubular epithelial cells and neutrophilsBlood/UrineEarly AKI detection and risk prediction; differentiation of intrinsic from prerenal AKI; prediction of non-recovery, RRT, and mortality; early indication of tubular injury before eGFR declineVariable performance across clinical settings; affected by comorbidities, measurement timing, cutoff values, and systemic inflammationKIM-1104,105Proximal tubular epithelial cellsUrineEarly detection of proximal tubular injury; assessment of AKI severity and duration; prediction of dialysis and mortalityVariable performance across clinical settings; limited independent prognostic value; further validation in larger populations is requiredCystatin C106,107Nucleated cellsBloodEarly detection of GFR decline; assessment of renal function; may indicate functional deterioration earlier than serum creatinineAffected by nonrenal factors; does not identify the site or cause of kidney injury; prognostic performance for AKI outcomes is inconsistentIL-18108,109Immune cells and injured tubular cellsBlood/UrineEarly detection and risk prediction of inflammatory or ischemic AKI; assessment of AKI severity and adverse outcomes, including mortalityVariable diagnostic performance across clinical settings; influenced by measurement timing and systemic inflammation; limited kidney specificity Comparison of S100A8/A9 with Established Kidney Injury Biomarkers Etiological Differentiation S100A8/A9 enables reliable discrimination between different etiologies of kidney injury, particularly in distinguishing inflammatory from non-inflammatory conditions. In AKI, urinary S100A8/A9 levels are markedly elevated in intrinsic renal injury compared with prerenal azotemia, demonstrating superior diagnostic performance relative to NGAL and without requiring normalization to creatinine.14,81–83 This likely reflects its closer association with inflammatory processes rather than tubular stress alone. Consistently, pediatric studies show higher levels in structural versus functional AKI,84–86 supporting its role as a robust discriminator; this utility is further validated in transplant populations, although specificity may be reduced in transplant recipients due to immune activation.87 Beyond AKI, S100A8/A9 also shows utility in differentiating infectious conditions. In urinary tract infections, urinary S100A8/A9 levels are higher in lower tract infections (eg, cystitis) compared with upper tract involvement, while serum levels correlate with systemic inflammatory markers such as C-reactive protein and procalcitonin.88 These findings indicate that S100A8/A9 may assist in both diagnosis and anatomical stratification of infection. In nephrolithiasis, proteomic studies have identified S100A8 and S100A9 in kidney stone matrices and crystal-associated protein profiles, supporting their association with stone formation.64,67,68 Notably, S100A8 and S100A9 are enriched in urinary extracellular vesicles from patients with calcium oxalate stones,16 suggesting that urinary extracellular vesicles may represent a promising non-invasive source for their detection. However, current evidence is based on small exploratory studies, and their diagnostic accuracy, specificity, and clinically applicable cutoff values remain to be established. Disease Activity Monitoring and Relapse Prediction S100A8/A9 functions as a potential biomarker reflecting disease activity and relapse risk, particularly in immune-mediated kidney diseases. In AAV, renal expression of S100A8/A9 correlates closely with histopathological activity, being highest in active lesions and lowest in sclerotic lesions.62 Circulating levels are elevated during active disease, remain above baseline during remission, and increase again prior to relapse, indicating persistent subclinical inflammation. Notably, higher levels are observed in relapsing patients compared with non-relapsing individuals. In MPO-ANCA-positive AAV, serum and urinary S100A8/A9 levels are also elevated during active disease and are associated with disease severity, further supporting their potential utility for disease activity assessment.66 Longitudinal studies further demonstrate that increases in serum S100A8/A9 levels are independently associated with subsequent renal function decline and higher relapse risk, particularly in PR3-associated disease.89 Similar associations have been reported in LN. Urinary S100A8/A9 levels and urine-to-serum ratios are elevated in patients with active LN, while combined serum S100A8/A9 and S100A12 showed potential for predicting response to rituximab at 6 months.60 In juvenile-onset SLE, serum S100A8/A9 levels are likewise higher in patients with active LN than in those with inactive or no renal involvement.65 In addition, glomerular S100A8 expression is markedly elevated in proliferative LN, suggesting an association with disease severity and activity.90 Collectively, these findings support the potential value of S100A8/A9 for assessing disease activity and, in selected settings, relapse risk or treatment response; however, further prospective validation is required before routine clinical application. Prognostic Prediction and Outcome Association S100A8/A9 is strongly associated with long-term outcomes across both inflammatory and malignant kidney diseases. In CKD, circulating S100A8/A9 levels are significantly elevated and independently correlate with vascular calcification, cardiovascular events, and mortality, suggesting its potential value for identifying patients at higher risk of adverse outcomes.19 In addition, fecal calprotectin has emerged as a potential predictor of mortality risk in CKD patients, with effects independent of traditional inflammatory markers.15 In RCC, elevated S100A8/A9 levels distinguish malignant from benign renal conditions and correlate with tumor stage, grade, and survival outcomes.63,70–73,91,92 Notably, S100A9 has been identified as an independent predictor of prognosis.63 Mechanistically, PTEN loss promotes an immunosuppressive tumor microenvironment via S100A9 upregulation, suggesting its potential as a biomarker of resistance to immunotherapy.73 In transplant recipients, circulating S100A8/A9 levels are associated with disease severity and renal function in the context of systemic inflammatory conditions such as COVID-19, further supporting its value as a potential biomarker for detecting subclinical allograft rejection.93 Special Clinical Contexts: Transplantation and Drug-Induced Injury The role of S100A8/A9 in specific clinical contexts appears to be complex and context-dependent. In kidney transplantation, elevated intragraft expression of S100A8/A9 during acute rejection has been paradoxically associated with improved long-term outcomes,94 possibly due to its immunomodulatory effects, including suppression of T-cell activation and modulation of dendritic cell function.95 In addition, S100A8/A9 is markedly upregulated in BK virus-associated allograft injury and correlates with early graft dysfunction, suggesting its utility in distinguishing viral infection from rejection or drug toxicity.96 In the context of drug-induced nephrotoxicity, urinary S100A8/A9 levels are elevated in patients receiving cisplatin-based chemotherapy, indicating renal stress or injury. However, its ability to predict overt nephrotoxicity remains limited, highlighting the need for multi-biomarker approaches.97 Collectively, S100A8/A9 represents a multifunctional biomarker with potential applications in early detection, etiological differentiation, disease monitoring, and prognostic assessment across kidney diseases. However, several challenges remain before its routine clinical implementation. Differences in biospecimen type, assay platform, normalization strategy, disease severity, and coexisting systemic inflammation may contribute to variability across clinical studies and hinder the establishment of universal diagnostic thresholds. Standardized detection methods, disease-specific cutoff values, and validation in large prospective cohorts are therefore required. Future studies incorporating S100A8/A9 into multi-biomarker panels may further improve its diagnostic specificity and translational value. Integration with metabolomics and other omics-based approaches may provide complementary molecular signatures of renal injury and inflammation, thereby facilitating biomarker discovery and patient stratification.110 Therapeutic Applications of Targeting S100A8/A9 in Kidney Diseases Emerging evidence supports the therapeutic potential of targeting the S100A8/A9 signaling axis across diverse kidney diseases (Figure 4). In IRI, pharmacological inhibition of the S100A8/A9-TLR4 pathway using small-molecule inhibitors such as tasquinimod, paquinimod, and ABR-238901 markedly reduces tubular necrosis, inflammatory responses, and short-term mortality, while also attenuating subsequent fibrotic remodeling.10,11 Similarly, in sepsis-associated AKI, blockade of S100A9 with paquinimod improves renal function and histological injury in a dose-dependent manner, highlighting its role in inflammation-driven epithelial damage.17 Figure 4Intervention strategies targeting the S100A8/A9 axis in kidney diseases. Small-molecule inhibitors, including tasquinimod, paquinimod, and ABR-238901, suppress S100A8/A9-related inflammatory signaling and show anti-inflammatory and renoprotective effects in preclinical models of IRI, sepsis-associated AKI, CKD-associated vascular calcification, and nephrocalcinosis. Natural products, such as Scrophularia striata ethanolic extract and Huangkui capsules, have been reported to reduce S100A8/A9 expression and associated inflammatory signaling in diabetic nephropathy. In clear cell RCC, inhibition of ATXN3 increases S100A8 ubiquitination and degradation, thereby reducing tumor-promoting signaling.A color-coded infographic titled Intervention strategies targeting S100A8/A9 is arranged in three vertical panels. Left panel (blue, Small molecule inhibitors): names and chemical sketches for tasquinimod, paquinimod and ABR-238901 appear at the top. Arrows depict these agents acting on an S100A8/A9 to TLR4 membrane interaction, leading to a decrease in inflammatory signaling (example pathways listed) and a final box indicating anti-inflammatory and kidney-protective outcomes. A bottom callout lists example disease contexts (ischemia to reperfusion injury, sepsis-related acute kidney injury, chronic kidney disease vascular calcification and kidney stones). Middle panel (green, Natural products): illustrations of a plant and a pill bottle accompany Scrophularia striata extract and Huangkui capsules. Downward arrows show reduced S100A8/A9 levels and reduced related inflammatory signaling, ending with a box stating less inflammation and renal damage; the application noted is diabetic nephropathy. Right panel (teal, Upstream regulators): a schematic shows blocking ATXN3, which increases S100A8 ubiquitination, leading to S100A8 breakdown and a concluding box indicating reduced tumor-supporting signaling; the application noted is clear cell renal cell carcinoma.Three-panel diagram showing drug, herbal and regulatory approaches to modulate S100A8/A9 pathways. Intervention strategies targeting the S100A8/A9 axis in kidney diseases. Small-molecule inhibitors, including tasquinimod, paquinimod, and ABR-238901, suppress S100A8/A9-related inflammatory signaling and show anti-inflammatory and renoprotective effects in preclinical models of IRI, sepsis-associated AKI, CKD-associated vascular calcification, and nephrocalcinosis. Natural products, such as Scrophularia striata ethanolic extract and Huangkui capsules, have been reported to reduce S100A8/A9 expression and associated inflammatory signaling in diabetic nephropathy. In clear cell RCC, inhibition of ATXN3 increases S100A8 ubiquitination and degradation, thereby reducing tumor-promoting signaling. In CKD, particularly in DN, selective inhibition of S100A8/A9 (eg, AB38b) effectively suppresses tubular EMT and interstitial fibrosis, suggesting a direct role in structural remodeling.18 Beyond synthetic inhibitors, natural compounds such as an ethanol extract of Scrophularia striata and Huangkui capsules have also been reported to confer renoprotective effects, partly by downregulating S100A8/A9 and its associated pathways, including RAGE signaling and oxidative stress, although their mechanisms remain less well defined.111,112 Furthermore, pharmacological inhibition of S100A9, including with paquinimod, attenuates vascular smooth muscle cell osteogenic differentiation and calcification, supporting the S100A8/A9 axis as a potential therapeutic target for CKD-associated vascular calcification.19 In renal malignancies, particularly clear cell RCC, modulation of S100A8/A9 stability represents an additional therapeutic angle. ATXN3 promotes S100A8 protein stability by suppressing its ubiquitination, thereby sustaining NF-κB activation and enhancing ccRCC cell proliferation, stemness, migration, and invasion. Targeting the ATXN3/S100A8/NF-κB axis may therefore represent a potential therapeutic strategy for ccRCC.92 Beyond malignanc, inhibition of S100A9 with paquinimod reduces CaOx crystal deposition in the kidneys of nephrocalcinosis mice and downregulates the expression of inflammatory factors.54 Collectively, these findings highlight multiple therapeutic approaches targeting S100A8/A9, including direct inhibition, receptor blockade, and upstream modulation. Importantly, most mechanistic and therapeutic findings are derived from animal models or in vitro systems, whereas human evidence is largely observational and focused on biomarker associations. Clinical studies directly evaluating S100A8/A9-targeted interventions in patients with kidney disease are currently lacking. In addition, the target specificity, renal pharmacokinetics, optimal dosing, and therapeutic window of available inhibitors remain poorly defined. Clinical studies conducted in nonrenal populations have reported anemia, fatigue, and cancer-related pain with tasquinimod,113 as well as arthralgia, headache, and elevated C-reactive protein levels with paquinimod.114 Moreover, systemic or prolonged inhibition of S100A8/A9 may impair antimicrobial defense or interfere with tissue repair. These limitations highlight the need for kidney-specific pharmacokinetic, toxicological, and clinical evaluation before translation into practice. Controversies and Unresolved Issues Despite substantial progress, several key controversies and unresolved issues remain regarding the role of S100A8/A9 in kidney diseases. One major challenge lies in its context- and time-dependent dual functionality. While S100A8/A9 clearly drives early inflammatory injury, particularly in acute settings such as IRI, it also appears to facilitate tissue repair during later phases by promoting macrophage polarization and epithelial recovery. However, evidence supporting this reparative role remains largely indirect, and the molecular basis of this stage-dependent functional shift remains unresolved, highlighting the need for temporally resolved, cell-specific, and receptor-specific studies. Another unresolved issue concerns the relative contribution and specificity of its receptors, particularly TLR4 and RAGE. Although both receptors mediate S100A8/A9 signaling, their downstream effects often overlap and vary across disease contexts, cell types, and stages of injury. The extent to which these pathways are redundant, synergistic, or functionally distinct remains incompletely defined, limiting the development of receptor-specific interventions. The cellular sources and release mechanisms of S100A8/A9 in different renal microenvironments are not fully understood. While myeloid cells are the predominant producers, emerging evidence suggests that non-myeloid cells, including TECs, may contribute under stress conditions. The relative importance of passive release versus active secretion, and how these modes influence downstream signaling, requires further clarification. More broadly, many mechanistic conclusions are derived from single disease models, small experimental cohorts, or studies examining S100A8 or S100A9 individually rather than the heterodimer, which may limit their generalizability. Apparently conflicting findings may therefore reflect differences in injury stage, cellular source, receptor expression, local concentration, and experimental design rather than a genuine biological contradiction. From a translational perspective, although S100A8/A9 shows promise as a biomarker, challenges remain regarding specificity and standardization. Its levels can be influenced by systemic inflammation, comorbid conditions, disease severity, and treatment status, which potentially limits its diagnostic precision in complex clinical settings such as sepsis or renal transplantation.74,87 In addition, most biomarker studies are observational and heterogeneous with respect to biospecimen type, assay platform, normalization method, and clinical population, making direct comparisons difficult and hindering the establishment of validated disease-specific cutoff values. Finally, therapeutic strategies targeting S100A8/A9 are still at an early stage of development. Preclinical studies demonstrate renoprotective effects of inhibiting the S100A8/A9-TLR4/RAGE axis; however, the optimal timing, dosage, and patient selection are unclear. Importantly, given its role in host defense and tissue repair, long-term inhibition may carry unintended consequences, including impaired immune responses or delayed healing. Addressing these challenges will require temporally resolved and cell-specific mechanistic studies to distinguish the injurious and reparative functions of S100A8/A9, together with receptor-selective approaches to clarify the relative contributions of TLR4 and RAGE. Standardized assays, disease-specific cutoff values, and validation in large longitudinal cohorts are needed to improve its clinical utility as a biomarker. In parallel, kidney-specific pharmacokinetic and toxicological studies, careful definition of therapeutic windows, and the development of spatiotemporally controlled interventions will be essential for safe clinical translation. Conclusion and Prospect S100A8/A9 has emerged as a key regulator linking inflammation, immune responses, and tissue remodeling in kidney diseases. Beyond serving as a potential biomarker, it actively drives inflammatory amplification, tubular injury, and fibrosis, while also contributing to tissue repair in a context- and time-dependent manner. This dual functionality highlights its complex role within the renal microenvironment and supports a unifying spatiotemporal framework. Clinically, the consistent elevation of S100A8/A9 in blood and urine underscores its potential for non-invasive diagnosis, risk stratification, and disease monitoring. However, several challenges remain, including incomplete understanding of its cell-specific sources, receptor-specific signaling, and optimal therapeutic window. Future efforts should integrate mechanistic and translational studies to clarify receptor-specific signaling, cell-specific functions, and the optimal therapeutic timing of S100A8/A9-targeted interventions. Standardized biomarker assays, disease-specific cutoff values, and validation in longitudinal clinical cohorts are also required. In parallel, renal pharmacokinetic and safety assessments should guide the development of receptor-selective, spatiotemporally controlled, and cell-specific strategies. Advances in precision medicine, multi-omics, single-cell analysis, and spatial biology may help resolve the heterogeneity of S100A8/A9 signaling and facilitate its clinical application in precision nephrology.